Lamivudine is a medication used to treat HIV infection. It works by stopping the virus from copying itself inside the body. It's often taken as a pill, usually once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Lamivudine for HIV Infection?
Lamivudine, sold under the brand name Epivir and as a generic, is an antiviral medicine used to treat HIV (human immunodeficiency virus) in adults and in children from 3 months of age. It is never used on its own for HIV. It is always one part of a combination of HIV medicines, called antiretroviral therapy, because HIV quickly becomes resistant to any single drug. Treatment does not cure HIV, but it lowers the amount of virus in the body, protects the immune system and reduces the chance of AIDS (acquired immunodeficiency syndrome, the advanced stage of HIV) and other HIV-related illness. Many people take lamivudine without seeing its name on the bottle, because it is built into several combination tablets. Dovato pairs it with dolutegravir and is approved as a complete two-drug regimen for some adults and adolescents, either as a first treatment or as a switch for people whose virus is already well controlled. Triumeq combines it with abacavir and dolutegravir. A lower-dose lamivudine tablet (100 mg, formerly sold as Epivir-HBV and now available as a generic) is approved for chronic hepatitis B, a long-term liver infection. It is rarely a first choice for hepatitis B today, because the virus often becomes resistant to it over time, and US liver specialists prefer options such as entecavir or tenofovir.
HIV is a retrovirus: to multiply, it has to copy its genetic material into DNA using an enzyme called reverse transcriptase, and then insert that DNA into the person's immune cells. Lamivudine belongs to a group called nucleoside reverse transcriptase inhibitors (NRTIs). Inside the cell, it is converted into an active form that looks like one of the building blocks of DNA. When reverse transcriptase picks it up, the growing DNA chain stops, so the virus cannot finish copying itself. Fewer new viruses means less damage to CD4 cells, the white blood cells HIV attacks, and over time the immune system can recover. The hepatitis B virus also relies on a reverse transcriptase step, which is why the same drug works against it at a lower dose.
For HIV, adults usually take 300 mg a day, either as one 300 mg tablet once a day or as 150 mg twice a day, with or without food. Children's doses are based on body weight, and a liquid is available for those who cannot swallow tablets, although tablets are preferred when a child can take them. People with reduced kidney function need a lower dose, because the kidneys clear lamivudine from the body. When lamivudine is part of a combination tablet such as Dovato or Triumeq, the dose is fixed in that tablet and follows that product's instructions. The HIV-strength product and the lower-dose hepatitis B product contain the same drug but are not interchangeable. The hepatitis B dose is too low to control HIV, and taking it with undiagnosed or untreated HIV can quickly make the virus resistant. This is one reason people starting lamivudine for hepatitis B are offered an HIV test. Taking every dose matters more than the exact time of day. Skipping doses, or stopping even for a short while, gives HIV a chance to become resistant to lamivudine and other drugs in the regimen. If a dose is missed, take it when you remember, but do not double up on the next one.
Lamivudine is generally well tolerated. In clinical trials, the most common complaints were headache, nausea, tiredness, diarrhea, a stuffy or runny nose and cough, although trials combined it with other HIV drugs, so not every symptom comes from lamivudine itself. Trouble sleeping, dizziness and low mood can also occur. These often ease, but symptoms that are severe or do not go away are worth raising with the care team. A new rash should be reported promptly. Two uncommon problems need quick attention. Lactic acidosis, a buildup of acid in the blood that can come with a severely enlarged, fatty liver, has been reported with this class of medicines and can be serious; it has occurred more often in women and people with obesity. Signs include unusual tiredness or weakness, muscle pain, shortness of breath, stomach pain with nausea and vomiting, feeling cold in the arms or legs, or a fast or irregular heartbeat. Pancreatitis (inflammation of the pancreas) is uncommon and has been a particular concern in children with risk factors; ongoing stomach pain that spreads to the back, especially with vomiting, is a warning sign. If either set of symptoms appears, call the prescriber right away.
The most important warning concerns hepatitis B. Because lamivudine also suppresses hepatitis B, people who have both HIV and hepatitis B can have a sudden, severe hepatitis B flare after stopping it or switching to an HIV regimen without it, and some flares have been fatal. Anyone with HIV should be tested for hepatitis B before or when starting a lamivudine regimen. People with both infections usually need a regimen that treats hepatitis B with more than lamivudine alone, since hepatitis B can become resistant to it. They should not stop lamivudine without their clinician, and they need liver blood tests for several months after any change. Yellowing of the skin or eyes, dark urine, pale stools or pain in the upper right side of the abdomen should prompt a call to the care team right away. Lamivudine has relatively few drug interactions. Sorbitol, a sugar alcohol used as a sweetener in some liquid medicines, can lower lamivudine levels, so long-term use of sorbitol-containing products is best avoided when possible. The other medicines in a combination regimen often have more interactions than lamivudine does, so the pharmacist should review every prescription, over-the-counter medicine and supplement. Lamivudine should not be taken by anyone who has had an allergic reaction to it. Lamivudine has been widely used during pregnancy. Registry data covering more than 11,000 pregnancies have not shown a higher rate of birth defects than in the general population. The US label advises people with HIV not to breastfeed while taking it, because HIV and the medicine can pass to the baby in breast milk; anyone pregnant or planning a pregnancy should discuss feeding plans and the overall regimen with their HIV clinician.
Lamivudine starts reducing the amount of HIV in the blood quickly, but the full effect is measured over weeks to months. The care team tracks viral load, the amount of HIV in a blood sample, and CD4 count, a measure of immune strength. The goal is to bring the viral load down to a very low level and keep it there, so regular checks continue even after treatment is working, along with other routine blood tests the care team orders. In the first weeks to months of HIV treatment, a recovering immune system can react to infections that were already hidden in the body, causing fever or other new signs of infection. This is called immune reconstitution syndrome, and new symptoms of infection during this period should be reported promptly. HIV treatment is long term and continues even when a person feels well. Feeling well is a sign that the regimen is working, not a reason to stop it, and any change in medicines should be planned with the HIV clinician, especially for people who also have hepatitis B.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Lamivudine, what you've noticed, or ask the community a question.